I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Edward W Gabrielson, M.D.
Attending Pathologist, Johns Hopkins Hospital
Professor of Pathology
Expertise: Breast Cancer, Esophageal Cancer, Lung Cancer, Pathology
Research Interests: Breast cancer; Biomarkers; Esophageal cancer; Lung cancer
The Koch Cancer Research Building
1550 Orleans Street Baltimore, MD 21231
Dr. Edward W. Gabrielson is a Professor of Pathology and Oncology at the Johns Hopkins University School of Medicine and Professor of Environmental Health Engineering at the Johns Hopkins Bloomberg School of Public Health. He specializes in molecular pathology, with particular emphasis on the pathology of breast, esophageal and lung cancers. Dr. Gabrielson is a member of the Johns Hopkins Kimmel Cancer Center.
He received his M.D. from Northwestern University, completed a residency in pathology at the University of Colorado School of Medicine, followed by a fellowship in pathology at the National Institutes of Health.
Dr. Gabrielson has authored or co-authored approximately 200 peer-reviewed publications, and is board certified in Anatomic and Clinical Pathology.
- Attending Pathologist, Johns Hopkins Hospital
- Attending Pathologist, Johns Hopkins Bayview Medical Center
- Professor of Pathology
- Professor of Oncology
- MD; Medicine, Northwestern University Feinberg School of Medicine (1977)
- University of Colorado School of Medicine / Pathology (1982)
- National Institutes of Health / Pathology (1985)
- American Board of Pathology / Anatomic & Clinical Pathology (1983)
- Licensed Physician and Surgeon, State of Maryland (1984, 2016)
Research & Publications
Dr. Gabrielson investigates the molecular biology of breast cancer and lung cancer, emphasizing aspects that have potential clinical significance. Current areas of emphasis include molecular classification of cancers, genetic instability in cancer, and functional changes in cancers related to cell-cell interactions and cellular metabolism.
Dr. Gabrielson’s lab has researched chromosomal changes in cancers, leading to the recognition that most cancers have an intrinsic instability of their genome. The lab has characterized chromosomal instability in breast cancer, recognizing that cancers with high levels of instability have mitotic spindle damage checkpoint defects. These cells also have unexpectedly high expression of mitotic spindle checkpoint genes, and the lab has investigated how the high expression of these genes is critical for survival of these genetically unstable cancer cells.
The Gabrielson lab also works on cellular metabolism of cancer. Ongoing investigations include the study of fatty acid metabolism in cancer and the protective functions of the Nrf2 signaling pathway. We are now also undertaking both laboratory and clinical investigations to determine the therapeutic potential of biguanide drugs in lung cancer therapy.
Finally, the laboratory is a part of a multidisciplinary team investigating the potential for immunotherapy in lung cancer treatment. By evaluating tissue specimens from patients treated with checkpoint blockade therapy, we hope to develop markers to predict responses to these promising therapies.
Technology Expertise KeywordsLung cancer; breast cancer; molecular biology; cell biology
Selected PublicationsView all on Pubmed
Li QK, Singh A, Biswal S, Askin F, Gabrielson E. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet; 56: 230-4, 2011
Daniel J, Coulter J, Woo JH, Wilsbach K, Gabrielson E. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci U S A; 108: 5384-9, 2011
Lemmon, C. R., Woo, J. H., Tully, E., Wilsbach, K., and Gabrielson, E. Nuclear factor-kappaB (NF-kappaB) mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase. J Biol Chem, 286: 31457-31465, 2011
Jhaveri TZ, Woo J, Shang X, Park BH and Gabrielson E. AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget. 2015; 6(17):14754-14765
Gniadek TJ, Li QK, Tully E, Chatterjee S, Nimmagadda S, Gabrielson E. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Mod Pathol. 2017;30:530-53
Academic Affiliations & Courses
Graduate Program Affiliation
Cellular and Molecular Medicine
Activities & Honors
- United States and Canadian Academy of Pathology
- International Association for the Study of Lung Cancer
- Lungevity Foundation